Publications

Kim JD, Lee AR, Moon DH, Chung YU, Hong SY, Cho HJ, Kang TH, Jang YH, Sohn MH, Seong BL* and Seo SU*., “Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus.”, Emerging Microbes & Infections. 2024, VOL. 13, 2343910. doi: 10.1080/22221751.

Kim NH, Kang S, Park GH, Shim G, Kang TH*, Yu YG*., “A robust antibody discovery platform for difficult-to-express G protein-coupled receptors.”, Protein Sci. 2023 Jan;32(1):e4520. doi: 10.1002/pro.4520.

Kim J, Lee JY, Kim HG, Kwak MW, Kang TH*., “Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic”, Int J Mol Sci. 2021 Aug 31;22(11):9489. doi: 10.3390/ijms22179489

Kang TH, Seong BL., “Solubility, stability and avidity of recombinant antibody fragments expressed in microorganisms”, Frontiers in Microbiology. 2020 Sep 25; 11:1927, doi:10.3389/fmicb.2020.01927

Kang TH, Jung ST., “Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer”, Biomolecules. 2020 Mar 1; 10(3), 382, doi:10.3390/biom10030382

Lee J, Karamitros C, Li W, Marshall NM, Lungu O, Miklos AE, Xu J, Kang TH, Lee C, Tan B, Hughes RA, Jung ST, Ippolito G, Gray J, Zhang Y, Kuhlman B, Georgiou G, Ellington AD., “Computer-based Engineering of Thermostabilized Antibody Fragments”, AIChE journal, 2019 Nov 19; doi: 10.1002/aic.16864

Kang TH, Jung ST., “Boosting therapeutic potency of antibodies by taming Fc domain functions”, Exp Mol Med. 2019 Nov 18; 51, 138, doi:10.1038/s12276-019-0345-9

Lee CH†, Kang TH†, Godon O, Watanabe M, Delidakis G, Gillis C, Cogné M, Macdonald L, Mutphy A, Werf S, Lee J, McDaniel J, Meyer A, Bruhns P, and Georgiou G., “An Engineered, pH-Toggle Switch, Human Fc Domain for Ultra-Long Circulation Persistence”, Nature Communications, 2019 Nov;10:5031. doi: 10.1038/s41467-019-13108-2
†These authors contributed equally.

Kang TH†, Lee CH†, Delidakis G, Jung J, Goff O, Lee J, Kim JE, Charab W, Bruhns P, and Georgiou G., “An Engineered Human Fc variant with Exquisite Selectivity for FcγRIIIaV158 Reveals that Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis with GM-CSF-differentiated Macrophages”, Front. Immunol. 2019 Mar 27;10:562. doi: 10.3389/fimmu.2019.00562
†These authors contributed equally.

Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G., “IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.”, Nat Immunol. 2017 Aug;18(8):889-898.

Raymond D, Stewart S, Lee J, Ferdman J, Bajic G, Do KT, Ernandes MJ, Settembre EC, Dormitzer PR, Giudice GD, Finco O, Kang TH, Ippolito GC, Georgiou G, Kepler TB, Haynes BF, Moody MA, Liao H, Schmidt AG, Harrison SC., “Influenza immunization elicits hemagglutinin antibodies specific for an egg-adapted vaccine strain”, Nat Med. 2016 Dec;22(12):1465-1469.

Kang TH, Kim HJ., “Farwell to animal testing: Innovations on human intestinal microphysiological systems.”, Micromachines 2016 June; 7(7), 107; doi:10.3390/mi7070107.

Kelton W, Mehta N, Charab W, Lee J, Lee CH, Kojima T, Kang TH, Georgiou G., “IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions.”, Chem Biol. 2014 Dec 18;21(12):1603-9.
• Commentary by Kai-Jye Lou, “BOOSTING IgG WITH IgA”. BioCentury Innovations for Jan 15, 2015

Jung ST, Kang TH, Kim D., “Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding.”, Biotechnology and Bioprocess Engineering. 2014 Sep;19(5):780-89.

Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, Sarkar CA, Georgiou G., “Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity.”, ACS Chem Biol. 2013 Feb 15;8(2):368-75.

Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G., “Revisiting the Role of Glycosylation in the Structure of Human IgG Fc.”, ACS Chem Biol. 2012 Sep 21;7(9):1596-602.

Jung ST, Kang TH, Kelton W, Georgiou G., “Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy.”, Curr Opin Biotechnol. 2011 Dec;22(6):858-67.

Makino T, Skretas G, Kang TH, Georgiou G., “Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies.”, Metab Eng. 2011 Mar;13(2):241-51.

Jung ST†, Kang TH†, Georgiou G., “Efficient expression and purification of human aglycosylated Fcgamma receptors in Escherichia coli.”,Biotechnol Bioeng. 2010 Sep 1;107(1):21-30.
†Sang Taek Jung and Tae Hyun Kang contributed equally to this work.

Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G.,”Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells.”, Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):604-9.
• Research Highlight: Nature Biotechnol. 28:45 (2010)|
• Commentary by Osherovich, L. SciBX 3(3); doi:10.1038/scibx.2010.73

Choi SI, Han KS, Kim CW, Ryu KS, Kim BH, Kim KH, Kim SI, Kang TH, Shin HC, Lim KH, Kim HK, Hyun JM, Seong BL., “Protein solubility and folding enhancement by interaction with RNA.”, PLoS One. 2008 Jul 16;3(7):e2677.